Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by journal name.
Page 5: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
1201 | 15 | 27 | 608 1997 INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 19(5):289-296 Pham-Huy C; Galons H; Voisin J; Zhu JR; Righenzi S; Warnet JM; Claude JR; Duc HT In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A | 1 | 1 |
1202 | 0 | 0 | 18 1981 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 49(4):511-512 PIPER LM; AGRAWAL KC; HASTINGS RC ANTI-INFLAMMATORY IMMUNOSUPPRESSIVE THALIDOMIDE ANALOGS - SCREENING | 0 | 0 |
1203 | 0 | 0 | 19 1981 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 49(4):512-512 AGRAWAL KC; HASSAN KM; HASTINGS RC STRUCTURE ACTIVITY RELATIONSHIP STUDIES OF THALIDOMIDE ANALOGS AS ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE AGENTS | 0 | 0 |
1204 | 0 | 0 | 153 1985 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 53(1):165-166 SHANNON EJ; TRUMAN RW; CHRISTY SA; VADIEE R; HASTINGS RC EFFECT OF THALIDOMIDE ON INDUCTION OF ANTIBODY-SYNTHESIS IN MICE TO A T-INDEPENDENT ANTIGEN - DNP FICOLL | 0 | 0 |
1205 | 1 | 20 | 154 1985 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 53(2):201-205 MONCADA B; BARANDA ML; GONZALEZAMARO R; URBINA R; LOREDO CE THALIDOMIDE - EFFECT ON T-CELL SUBSETS AS A POSSIBLE MECHANISM OF ACTION | 31 | 42 |
1206 | 0 | 6 | 233 1988 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 56(4):625-625 SALAFIA A; KHARKAR RD THALIDOMIDE AND EXFOLIATIVE DERMATITIS | 6 | 6 |
1207 | 5 | 14 | 705 1998 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 66(1):61-65 Moreira AL; Kaplan G; Villahermosa LG; Fajardo TJ; Abalos RM; Cellona RV; Balagon MVF; Tan EV; Walsh GP Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL | 1 | 9 |
1208 | 7 | 20 | 1733 2003 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11(6):785-790 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Effects of thalidomide on the expression of angiogenesis growth factors in human A(549) lung adenocarcinoma cells | 0 | 0 |
1209 | 9 | 21 | 609 1997 INTERNATIONAL JOURNAL OF ONCOLOGY 10(5):965-969 Nguyen M; Tran C; Barsky S; Sun JR; McBride W; Pegram M; Pietras R; Love S; Glaspy J Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies | 20 | 26 |
1210 | 5 | 41 | 1734 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 22(1):165-173 Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1211 | 13 | 23 | 1735 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 23(6):1651-1655 Kaicker S; McCrudden KW; Beck L; New T; Huang JZ; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma | 0 | 0 |
1212 | 0 | 28 | 3 1980 INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY 18:403-409 KLASINC L; TRINAJSTIC N; KNOP JV APPLICATION OF PHOTOELECTRON-SPECTROSCOPY TO BIOLOGICALLY-ACTIVE MOLECULES AND THEIR CONSTITUENT PARTS .8. THALIDOMIDE | 0 | 0 |
1213 | 14 | 23 | 1917 2004 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 60(2):353-357 Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme | 0 | 0 |
1214 | 0 | 0 | 308 1991 INTERNATIONAL JOURNAL OF STD & AIDS 2(5):369-370 FULLER GN; JACOBS JM; GUILOFF RJ THALIDOMIDE, PERIPHERAL NEUROPATHY AND AIDS | 5 | 7 |
1215 | 1 | 13 | 535 1996 INTERNATIONAL JOURNAL OF STD & AIDS 7(7):518-520 Lewis DA; Amerasinghe CN; Murphy SM Successful treatment of Behcet's syndrome in an African female patient with thalidomide | 2 | 3 |
1216 | 6 | 28 | 706 1998 INTERNATIONAL JOURNAL OF STD & AIDS 9(12):751-755 Fife K; Howard MR; Gracie F; Phillips RH; Bower M Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre | 29 | 45 |
1217 | 9 | 29 | 818 1999 INTERNATIONAL JOURNAL OF TOXICOLOGY 18(5):337-352 Teo SK; Trigg NJ; Shaw ME; Morgan JM; Thomas SD Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration | 7 | 7 |
1218 | 19 | 30 | 1474 2002 INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 6(7):569-572 Fu LM; Fu-Liu CS Thalidomide and tuberculosis | 2 | 3 |
1219 | 11 | 19 | 1475 2002 INVESTIGATIONAL NEW DRUGS 20(4):389-393 Minor DR; Monroe D; Damico LA; Meng G; Suryadevara U; Elias L A phase II study of thalidomide in advanced metastatic renal cell carcinoma | 7 | 10 |
1220 | 14 | 32 | 1736 2003 INVESTIGATIONAL NEW DRUGS 21(3):359-366 Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Dalla Costa T; Di Leone LP; Schwartsmann G Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1221 | 0 | 0 | 363 1993 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 34(4):1479-1479 YAN GC; PITTET N; HERBORT CP THE EFFECT OF THALIDOMIDE ON ENDOTOXIN-INDUCED UVEITIS IN RATS | 0 | 0 |
1222 | 0 | 0 | 407 1994 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 35(4):1996-1996 DAMATO RJ; LOUGHMAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 0 | 0 |
1223 | 0 | 0 | 464 1995 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 36(4):S225-S225 DAMATO RJ; KENYON BM FURTHER-STUDIES EXAMINING THE EFFECTS OF THALIDOMIDE ON ANGIOGENESIS | 0 | 0 |
1224 | 0 | 0 | 536 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):546-546 Ozaki S; Yamana T; Kita M; Honda Y Effect of thalidomide on experimental choroidal neovascularization in pigmented rats | 0 | 0 |
1225 | 0 | 0 | 537 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):572-572 Tsujikawa M; Saito Y; Tatebayashi M; Tano Y The inhibitory effect of thalidomide for experimental preretinal neovascularization by laser-induced venous occlusion in rats. | 0 | 0 |
1226 | 0 | 0 | 538 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):3032-3032 Lansing MB; Dixit S; Glaser BM The effect of systemic thalidomide and amiloride on neovascularization in the rabbit corneal micropocket essay | 0 | 0 |
1227 | 0 | 0 | 539 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):4015-4015 Zhang EP; Pleyer U; Hoffmann F; Hartmann C Effect of thalidomide on experimental keratoplasty | 0 | 0 |
1228 | 0 | 0 | 610 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1240-1240 Lesk MR; Ponomarenko S; Filion B; Burnier M Effect of oral thalidomide on prolongation of rabbit sclerostomy function. | 0 | 0 |
1229 | 0 | 2 | 611 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1680-1680 Joussen AM; Kruse FE; Becker M; Rohrschneider K; Volcker HE Thalidomide inhibits angiogenesis induced by vascular endothelial growth factor | 0 | 0 |
1230 | 0 | 0 | 612 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):4467-4467 DAmato RJ; Verheul HMW; Panigrahy D; Yuan J Combination antiangiogenic therapy with thalidomide and nonsteroidal anti-inflammatory drugs (NSAIDs) | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1231 | 0 | 0 | 613 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):5409-5409 Baatz H; Tonnessen B; Pleyer U; Hartmann C Thalidomide inhibits leukocyte-endothelium-interaction in endotoxin-induced uveitis | 0 | 0 |
1232 | 0 | 0 | 819 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S84-S84 Velez G; Robinson MR; Durbin T; Yuan P; Sung C; Whitcup SM Thalidomide-sustained release devices for choroidal neovascularization; An in-vitro analysis | 0 | 1 |
1233 | 0 | 0 | 820 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S224-S224 Spraul CW; Kaven C; Amann J; Lang GK; Lang GE Effect of thalidomide, octreotide, and decortine on the migration and proliferation of RPE cells in vitro | 0 | 0 |
1234 | 0 | 0 | 993 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S180-S180 Velez G; King BA; Yuan P; Whitcup SM; Robison MR Thalidomide analogue (EM-138) sustained release implants to treat choroidal neovascularization associated with macular degeneration | 0 | 0 |
1235 | 0 | 0 | 994 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Spraul CW; Kaven C; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human RPE cell proliferation. | 0 | 0 |
1236 | 0 | 0 | 995 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Jakobezyk-Zmija M; Kaven C; Spraul CW; Lang GK; Lang GE Effect of thalidomide and prednisolone on the secretion of growth factors by human RPE cells in vitro | 0 | 0 |
1237 | 0 | 0 | 996 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S684-S684 Tham VMB; Tong JT; Giese MJ; Tran MK; Fardin B; Taban R; Rayner SA; Mondino BJ The effect of thalidomide on corneal graft rejection in rabbit eyes | 0 | 0 |
1238 | 0 | 0 | 1215 2001 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 42(4):S233-S233 Maguire MG; Fine SL; Maguire AM; D'Amato RJ; Singerman LJ Results of the age-related macular degeneration and thalidomide study (AMDATS). | 0 | 5 |
1239 | 12 | 25 | 1216 2001 ISRAEL MEDICAL ASSOCIATION JOURNAL 3(9):644-648 Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R Amelioration of experimental colitis by thalidomide | 1 | 1 |
1240 | 0 | 6 | 278 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1467-1468 RANDALL T THALIDOMIDE BACK IN THE NEWS, BUT IN MORE FAVORABLE CIRCUMSTANCES | 7 | 21 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1241 | 0 | 2 | 279 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1473-1473 RANDALL T RESEARCH FOCUSES ON IMMUNOSUPPRESSIVE EFFECT, UNKNOWN TERATOGENIC MECHANISM OF THALIDOMIDE | 2 | 2 |
1242 | 0 | 1 | 280 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1474-1474 RANDALL T INVESTIGATIONAL NEW DRUG (US) ORPHAN TRIALS NOW USE THALIDOMIDE FROM 2 SOURCES | 8 | 12 |
1243 | 0 | 0 | 614 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(5):379-379 Nightingale SL Workshop on thalidomide | 0 | 0 |
1244 | 0 | 0 | 615 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(14):1135-1137 Marwick C Thalidomide back - Under strict control | 10 | 13 |
1245 | 0 | 0 | 707 1998 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 280(10):872-872 Nightingale SL Thalidomide approved for erythema nodosum leprosum | 9 | 11 |
1246 | 0 | 0 | 1217 2001 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 286(8):909-909 Mitka M Thalidomide battles myeloma | 1 | 0 |
1247 | 14 | 28 | 1476 2002 JAPANESE JOURNAL OF CANCER RESEARCH 93(9):1029-1036 Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome | 3 | 3 |
1248 | 0 | 0 | 210 1987 JAPANESE JOURNAL OF PSYCHIATRY AND NEUROLOGY 41(2):197-206 KANNO O ELECTROENCEPHALOGRAPHIC STUDY OF 137 PATIENTS WITH THALIDOMIDE EMBRYOPATHY | 0 | 1 |
1249 | 12 | 27 | 821 1999 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
1250 | 40 | 51 | 997 2000 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 6(1):19-26 Lenardo TM; Calabrese LH The role of thalidomide in the treatment of rheumatic disease | 4 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1251 | 4 | 40 | 1477 2002 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 8(5):256-259 Barthel HR; Charrier U; Kramer M; Loch C Successful treatment of idiopathic febrile panniculitis (Weber-Christian disease) with thalidomide in a patient having failed multiple other medical therapies | 0 | 0 |
1252 | 4 | 9 | 1737 2003 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 9(2):96-98 Ching DWT; McClintock A; Beswick F Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I - Case report | 0 | 0 |
1253 | 17 | 19 | 998 2000 JOINT BONE SPINE 67(4):259-261 Wendling D; Toussirot E; Michel F Thalidomide: a comeback? | 1 | 4 |
1254 | 37 | 44 | 1218 2001 JOINT BONE SPINE 68(6):582-587 Combe B Thalidomide: new indications? | 1 | 3 |
1255 | 6 | 33 | 540 1996 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 11(3):247-257 Klausner JD; Makonkawkeyoon S; Akarasewi P; Nakata K; Kasinrerk W; Corral L; Dewar RL; Lane HC; Freedman VH; Kaplan G The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M-tuberculosis infection | 51 | 126 |
1256 | 0 | 0 | 616 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):20-20 Welles L; Little R; Wyvill K; Pluda J; Figg W; Lietzau J; Merced T; Humphrey R; Yarchoan R Preliminary results of a phase II study of oral thalidomide in patients with HIV infection and Kaposi's sarcoma (KS) | 2 | 3 |
1257 | 0 | 0 | 617 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):76-76 Bower M; Howard M; Gracie F; Phillips R; Fife K A phase II study of thalidomide for Kaposi's sarcoma: Activity and correlation with KSHV DNA load | 1 | 2 |
1258 | 3 | 4 | 618 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 15(5):392-392 Sharp M; Getty J; Klausner JD Thalidomide use is associated with weight gain in HIV-1-positive clients | 2 | 2 |
1259 | 0 | 0 | 619 1997 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 99(1):679-679 James DE; Jaffarian A; Biggs DF The effects of thalidomide on TNF alpha production from guinea pig alveolar macrophages in vitro and on airways' hyperresponsiveness in vivo. | 0 | 0 |
1260 | 0 | 0 | 822 1999 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 103(1):S20-S20 Martinez A; Hernandez T; Hernandez V; Espinosa F Thalidomide for pertinacious vasculitic syndrome secondary to coxsackie A virus infection. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1261 | 0 | 42 | 118 1984 JOURNAL OF ANATOMY 139(OCT):397-410 MCCREDIE J; NORTH K; DEIONGH R THALIDOMIDE DEFORMITIES AND THEIR NERVE SUPPLY | 3 | 7 |
1262 | 18 | 23 | 620 1997 JOURNAL OF AOAC INTERNATIONAL 80(4):767-773 Reepmeyer JC; Cox DC Liquid chromatographic determination of thalidomide in tablets, capsules, and raw materials | 0 | 4 |
1263 | 6 | 33 | 259 1989 JOURNAL OF AUTOIMMUNITY 2(2):197-202 CRAIN E; MCINTOSH KR; GORDON G; PESTRONK A; DRACHMAN DB THE EFFECT OF THALIDOMIDE ON EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS | 7 | 9 |
1264 | 15 | 25 | 999 2000 JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 22 | 22 |
1265 | 27 | 53 | 1219 2001 JOURNAL OF BIOLOGICAL CHEMISTRY 276(25):22382-22387 Keifer JA; Guttridge DC; Ashburner BP; Baldwin AS Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity | 33 | 57 |
1266 | 10 | 41 | 1918 2004 JOURNAL OF BIOMEDICAL SCIENCE 11(5):591-598 Chen CS; Perng WC; Chen CW; Huang KL; Wu CP; Yen MH Thalidomide reduces lipopolysaccharide/zymosan-induced acute lung injury in rats | 0 | 0 |
1267 | 4 | 52 | 823 1999 JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME 81B(1):9-23 McCredie J; Willert HG Longitudinal limb deficiencies and the sclerotomes - An analysis of 378 dysmelic malformations induced by thalidomide | 0 | 8 |
1268 | 0 | 0 | 1738 2003 JOURNAL OF BONE AND MINERAL RESEARCH 18:S310-S310 Bose N; Bergemann H; Westendorf JJ; Rajkumar SV; Masellis AM Expression of alternatively spliced Runx2 in multiple myeloma patients and a shift in expression in response to thalidomide treatment. | 0 | 0 |
1269 | 16 | 34 | 1478 2002 JOURNAL OF CARDIAC FAILURE 8(5):306-314 Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure | 2 | 3 |
1270 | 39 | 67 | 1479 2002 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 6(2):160-174 Kumar S; Witzig TE; Rajkumar SV Thalidomide as an anti-cancer agent | 6 | 10 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1271 | 2 | 13 | 408 1994 JOURNAL OF CHEMICAL CRYSTALLOGRAPHY 24(1):95-99 CAIRA MR; BOTHA SA; FLANAGAN DR POLYMORPHISM OF N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE (THALIDOMIDE) - STRUCTURAL CHARACTERIZATION OF A 2ND MONOCLINIC RACEMIC MODIFICATION | 0 | 2 |
1272 | 1 | 5 | 1220 2001 JOURNAL OF CHEMICAL EDUCATION 78(6):759-761 Bennett N; Cornely K Thalidomide makes a comeback: A case discussion exercise that integrates biochemistry and organic chemistry | 0 | 3 |
1273 | 4 | 17 | 1000 2000 JOURNAL OF CHILD NEUROLOGY 15(8):497-503 Schoeman JF; Springer P; Ravenscroft A; Donald PR; Bekker LG; van Rensburg AJ; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible anti-inflammatory role | 8 | 11 |
1274 | 1 | 1 | 1001 2000 JOURNAL OF CHILD NEUROLOGY 15(12):838-838 Schoeman JF Thalidomide therapy in childhood tuberculous meningitis | 3 | 4 |
1275 | 13 | 26 | 1919 2004 JOURNAL OF CHILD NEUROLOGY 19(4):250-257 Schoeman JF; Springer P; van Rensburg AJ; Swanevelder S; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study | 0 | 0 |
1276 | 0 | 9 | 409 1994 JOURNAL OF CHROMATOGRAPHY A 666(1-2):235-240 KNOCHE B; BLASCHKE G INVESTIGATIONS ON THE IN-VITRO RACEMIZATION OF THALIDOMIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 20 | 31 |
1277 | 13 | 41 | 1002 2000 JOURNAL OF CHROMATOGRAPHY A 876(1-2):157-167 Meyring M; Chankvetadze B; Blaschke G Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography | 3 | 32 |
1278 | 8 | 18 | 824 1999 JOURNAL OF CHROMATOGRAPHY B 723(1-2):255-264 Meyring M; Strickmann D; Chankvetadze B; Blaschke G; Desiderio C; Fanali S Investigation of the in vitro biotransformation of R-(+)- thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS | 8 | 20 |
1279 | 9 | 9 | 825 1999 JOURNAL OF CHROMATOGRAPHY B 734(2):203-210 Torano JS; Verbon A; Guchelaar HJ Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection | 8 | 8 |
1280 | 16 | 24 | 1480 2002 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 767(1):145-151 Teo SK; Chandula RS; Harden JL; Stirling DI; Thomas SD Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry | 4 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1281 | 57 | 70 | 1739 2003 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
1282 | 3 | 19 | 465 1995 JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 674(2):287-292 Weinz C; Blaschke G Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis | 11 | 24 |
1283 | 0 | 12 | 211 1987 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 413:181-187 CZEJKA MJ; KOCH HP DETERMINATION OF THALIDOMIDE AND ITS MAJOR METABOLITES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 22 | 23 |
1284 | 4 | 15 | 260 1989 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 488(2):417-425 WINCKLER K; KLINKMULLER KD; SCHMAHL HJ DETERMINATION OF THE THALIDOMIDE ANALOGS 2-(2,6-DIOXOPIPERIDINE-3-YL)PHTHALIMIDINE (EM 12), 2-(2,6-DIOXOPIPERIDINE-4-YL)PHTHALIMIDINE (EM 16) AND THEIR METABOLITES IN BIOLOGICAL SAMPLES | 7 | 7 |
1285 | 3 | 9 | 324 1992 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 582(1-2):211-216 ERIKSSON T; BJORKMAN S; FYGE A; EKBERG H DETERMINATION OF THALIDOMIDE IN PLASMA AND BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - AVOIDING HYDROLYTIC DEGRADATION | 44 | 44 |
1286 | 10 | 15 | 1481 2002 JOURNAL OF CLINICAL GASTROENTEROLOGY 35(2):149-150 Kane S; Stone LJ; Ehrenpreis E Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab - A case series | 3 | 5 |
1287 | 10 | 27 | 1221 2001 JOURNAL OF CLINICAL IMMUNOLOGY 21(5):357-364 Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues | 3 | 4 |
1288 | 10 | 19 | 1482 2002 JOURNAL OF CLINICAL MICROBIOLOGY 40(6):2302-2304 Curley MJ; Hussein SA; Hassoun PM Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma | 0 | 0 |
1289 | 6 | 34 | 1003 2000 JOURNAL OF CLINICAL ONCOLOGY 18(4):708-715 Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WKA Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | 78 | 150 |
1290 | 13 | 67 | 1004 2000 JOURNAL OF CLINICAL ONCOLOGY 18(13):2593-2602 Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R Activity of thalidomide in AIDS-related Kaposis's sarcoma | 45 | 83 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1291 | 21 | 40 | 1005 2000 JOURNAL OF CLINICAL ONCOLOGY 18(14):2710-2717 Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF Phase II evaluation of thalidomide in patients with metastatic breast cancer | 39 | 54 |
1292 | 1 | 5 | 1006 2000 JOURNAL OF CLINICAL ONCOLOGY 18(19):3453-3453 Cohen MH Thalidomide in the treatment of high-grade gliomas | 1 | 3 |
1293 | 18 | 26 | 1222 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3593-3595 Rajkumar SV; Kyle RA Thalidomide in the treatment of plasma cell malignancies | 6 | 7 |
1294 | 7 | 22 | 1223 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3596-3601 Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P Treatment of Waldenstrom's macroglobulinemia with thalidomide | 17 | 28 |
1295 | 6 | 20 | 1483 2002 JOURNAL OF CLINICAL ONCOLOGY 20(1):302-306 Motzer RJ; Berg W; Ginsberg M; Russo P; Vuky J; Yu R; Bacik J; Mazumdar M Phase II trial of thalidomide for patients with advanced renal cell carcinoma | 22 | 36 |
1296 | 2 | 4 | 1484 2002 JOURNAL OF CLINICAL ONCOLOGY 20(4):1147-1149 Abramson N; Stokes PK; Luke M; Marks AR; Harris JM Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide | 0 | 3 |
1297 | 4 | 4 | 1485 2002 JOURNAL OF CLINICAL ONCOLOGY 20(5):1429-1430 Nathan PD; Gore ME; Eisen TG Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma | 8 | 12 |
1298 | 4 | 5 | 1486 2002 JOURNAL OF CLINICAL ONCOLOGY 20(8):2212-2212 Cany L; Fitoussi O; Boiron JM; Marit G Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma | 4 | 4 |
1299 | 20 | 24 | 1487 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2607-2609 Eisen T Thalidomide in solid malignancies | 6 | 12 |
1300 | 6 | 26 | 1488 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2610-2615 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial | 12 | 22 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1301 | 1 | 1 | 1489 2002 JOURNAL OF CLINICAL ONCOLOGY 20(15):3361-3361 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial (vol 20, pg 2610, 2002) | 0 | 0 |
1302 | 21 | 37 | 1490 2002 JOURNAL OF CLINICAL ONCOLOGY 20(21):4319-4323 Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | 33 | 57 |
1303 | 7 | 22 | 1740 2003 JOURNAL OF CLINICAL ONCOLOGY 21(1):16-19 Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | 32 | 59 |
1304 | 6 | 15 | 1741 2003 JOURNAL OF CLINICAL ONCOLOGY 21(11):2211-2214 Loprinzi C; Rajkumar SV Why not start with thalidomide? | 0 | 1 |
1305 | 4 | 37 | 1742 2003 JOURNAL OF CLINICAL ONCOLOGY 21(12):2299-2304 Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | 2 | 5 |
1306 | 5 | 37 | 1743 2003 JOURNAL OF CLINICAL ONCOLOGY 21(13):2551-2557 Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | 2 | 7 |
1307 | 7 | 25 | 1744 2003 JOURNAL OF CLINICAL ONCOLOGY 21(14):2732-2739 Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma | 4 | 11 |
1308 | 7 | 26 | 1745 2003 JOURNAL OF CLINICAL ONCOLOGY 21(17):3351-3356 Hwu WJ; Krown SE; Menell JH; Panageas KS; Merrell J; Lamb LA; Williams LJ; Quinn CJ; Foster T; Chapman PB; Livingston PO; Wolchok JD; Houghton AN Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma | 4 | 14 |
1309 | 13 | 36 | 1746 2003 JOURNAL OF CLINICAL ONCOLOGY 21(20):3770-3776 Hernberg M; Virkkunen P; Bono P; Atinen H; Maenpaa H; Joensuu H Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma | 2 | 4 |
1310 | 51 | 94 | 1747 2003 JOURNAL OF CLINICAL ONCOLOGY 21(23):4444-4454 Dimopoulos MA; Anagnostopoulos A; Weber D Treatment of plasma cell dyserasias with thalidomide and its derivatives | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1311 | 8 | 24 | 1920 2004 JOURNAL OF CLINICAL ONCOLOGY 22(3):424-431 Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial | 0 | 0 |
1312 | 9 | 42 | 1921 2004 JOURNAL OF CLINICAL ONCOLOGY 22(13):2532-2539 Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer | 0 | 0 |
1313 | 0 | 1 | 1922 2004 JOURNAL OF CLINICAL ONCOLOGY 22(14):2973-2973 Kumar Thalidomide: Current role in the treatment of non-plasma cell malignancies (vol 22, pg 2477, 20040 | 0 | 0 |
1314 | 9 | 16 | 1923 2004 JOURNAL OF CLINICAL ONCOLOGY 22(16):3212-3214 Richardson P; Anderson K Immunomodulatory analogs of thalidomide: An emerging new therapy in myeloma | 0 | 0 |
1315 | 17 | 32 | 1924 2004 JOURNAL OF CLINICAL ONCOLOGY 22(16):3269-3276 Schey SA; Fields P; Bartlett JB; Clarke IA; Ashan G; Knight RD; Streetly M; Dalgleish AG Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma | 1 | 1 |
1316 | 8 | 15 | 826 1999 JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
1317 | 20 | 32 | 1224 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(6):662-667 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Thalidomide dose proportionality assessment following single doses to healthy subjects | 3 | 4 |
1318 | 11 | 18 | 1225 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(10):1091-1097 Aweeka F; Trapnell C; Chernoff M; Jayewardene A; Spritzler J; Bellibas SE; Lizak P; Jacobson J Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251 | 6 | 7 |
1319 | 10 | 21 | 1491 2002 JOURNAL OF COMBINATORIAL CHEMISTRY 4(2):149-153 Xiao ZL; Schaefer K; Firestine S; Li PK Solid-phase synthesis of thalidomide and its analogues | 0 | 4 |
1320 | 1 | 20 | 155 1985 JOURNAL OF CRANIOFACIAL GENETICS AND DEVELOPMENTAL BIOLOGY 5(2):147-157 NEWMAN LM; HENDRICKX AG TEMPOROMANDIBULAR MALFORMATIONS IN THE BONNET MONKEY (MACACA-RADIATA) FETUS FOLLOWING MATERNAL INGESTION OF THALIDOMIDE | 0 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1321 | 9 | 9 | 1226 2001 JOURNAL OF DERMATOLOGICAL TREATMENT 12(3):145-147 Thomson KF; Goodfield MJD Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus | 0 | 2 |
1322 | 7 | 12 | 1748 2003 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22(4):129-133 Bernardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): Results, prognostic factors and side effects in eight patients previously treated with multiple myeloma | 0 | 0 |
1323 | 2 | 25 | 309 1991 JOURNAL OF EXPERIMENTAL MEDICINE 173(3):699-703 SAMPAIO EP; SARNO EN; GALILLY R; COHN ZA; KAPLAN G THALIDOMIDE SELECTIVELY INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY STIMULATED HUMAN MONOCYTES | 291 | 504 |
1324 | 1 | 19 | 364 1993 JOURNAL OF EXPERIMENTAL MEDICINE 177(6):1675-1680 MOREIRA AL; SAMPAIO EP; ZMUIDZINAS A; FRINDT P; SMITH KA; KAPLAN G THALIDOMIDE EXERTS ITS INHIBITORY-ACTION ON TUMOR-NECROSIS-FACTOR-ALPHA BY ENHANCING MESSENGER-RNA DEGRADATION | 236 | 431 |
1325 | 19 | 37 | 708 1998 JOURNAL OF EXPERIMENTAL MEDICINE 187(11):1885-1892 Haslett PAJ; Corral LG; Albert M; Kaplan G Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | 144 | 179 |
1326 | 13 | 25 | 1492 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
1327 | 10 | 18 | 1493 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(3):233-235 Selby W Thalidomide in inflammatory bowel disease: Too little, too soon | 0 | 0 |
1328 | 7 | 25 | 410 1994 JOURNAL OF HEPATOLOGY 21(4):496-499 MCCORMICK PA; SCOTT F; EPSTEIN O; BURROUGHS AK; SCHEUER PJ; MCINTYRE N THALIDOMIDE AS THERAPY FOR PRIMARY BILIARY-CIRRHOSIS - A DOUBLE-BLIND PLACEBO-CONTROLLED PILOT-STUDY | 6 | 11 |
1329 | 0 | 0 | 1227 2001 JOURNAL OF HEPATOLOGY 34:18-18 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
1330 | 10 | 30 | 621 1997 JOURNAL OF IMMUNOLOGY 159(10):5157-5161 Moller DR; Wysocka M; Greenlee BM; Ma XJ; Wahl L; Flockhart DA; Trinchieri G; Karp CL Inhibition of IL-12 production by thalidomide | 77 | 114 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1331 | 14 | 30 | 709 1998 JOURNAL OF IMMUNOLOGY 161(8):4236-4243 Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production | 34 | 50 |
1332 | 10 | 48 | 827 1999 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 80 | 127 |
1333 | 37 | 67 | 1494 2002 JOURNAL OF IMMUNOLOGY 168(6):2644-2651 Majumdar S; Lamothe B; Aggarwal BB Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester | 12 | 25 |
1334 | 23 | 42 | 1495 2002 JOURNAL OF IMMUNOLOGY 168(10):4914-4919 Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity | 14 | 29 |
1335 | 24 | 42 | 1925 2004 JOURNAL OF IMMUNOLOGY 172(8):5103-5109 Gockel HR; Lugering A; Heidemann J; Schmidt M; Domschke W; Kucharzik T; Lugering N Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway | 0 | 0 |
1336 | 8 | 18 | 1926 2004 JOURNAL OF IMMUNOTHERAPY 27(4):259-264 Elaraj DM; White DE; Steinberg SM; Haworth K; Rosenberg SA; Yang JC A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma | 0 | 0 |
1337 | 10 | 16 | 1749 2003 JOURNAL OF INFECTION 47(3):251-255 Roberts MTM; Mendelson M; Meyer P; Carmichael A; Lever AML The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports | 0 | 0 |
1338 | 4 | 10 | 325 1992 JOURNAL OF INFECTIOUS DISEASES 166(4):939-940 GEORGHIOU PR; ALLWORTH AM THALIDOMIDE IN PAINFUL AIDS-ASSOCIATED PROCTITIS | 11 | 21 |
1339 | 1 | 23 | 365 1993 JOURNAL OF INFECTIOUS DISEASES 168(2):408-414 SAMPAIO EP; KAPLAN G; MIRANDA A; NERY JAC; MIGUEL CP; VIANA SM; SARNO EN THE INFLUENCE OF THALIDOMIDE ON THE CLINICAL AND IMMUNOLOGICAL MANIFESTATION OF ERYTHEMA-NODOSUM LEPROSUM | 141 | 212 |
1340 | 3 | 15 | 466 1995 JOURNAL OF INFECTIOUS DISEASES 172(4):1137-1140 PETERSON PK; HU SX; SHENG WS; KRAVITZ FH; MOLITOR TW; CHATTERJEE D; CHAO CC THALIDOMIDE INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY LIPOPOLYSACCHARIDE-STIMULATED AND LIPOARABINOMANNAN-STIMULATED HUMAN MICROGLIAL CELLS | 20 | 33 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1341 | 9 | 41 | 710 1998 JOURNAL OF INFECTIOUS DISEASES 177(6):1563-1572 Tsenova L; Sokol K; Freedman VH; Kaplan G Combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death | 14 | 26 |
1342 | 6 | 17 | 828 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):61-67 Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N; Natl Inst Allergy Infect Dis AIDS Clin Trials G Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection | 27 | 38 |
1343 | 6 | 15 | 829 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):216-219 Meierhofer C; Dunzendorfer S; Wiederman CJ Protein kinase C-dependent effects on leukocyte migration of thalidomide | 5 | 10 |
1344 | 12 | 44 | 1007 2000 JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |
1345 | 1 | 1 | 1008 2000 JOURNAL OF INFECTIOUS DISEASES 181(4):1521-1521 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. (vol 181, pg 954, 2000) | 0 | 0 |
1346 | 9 | 15 | 1009 2000 JOURNAL OF INFECTIOUS DISEASES 181(5):1813-1816 Juffermans NP; Verbon A; Olszyna DP; van Deventer SJH; Speelman P; van der Poll T Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4(+) T cells in humans | 3 | 5 |
1347 | 8 | 8 | 1010 2000 JOURNAL OF INFECTIOUS DISEASES 182(2):639-639 Gori A; Rossi MC; Trabattoni D; Marchetti G; Fusi ML; Molteni C; Clerici M; Franzetti F Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection | 6 | 7 |
1348 | 4 | 5 | 1011 2000 JOURNAL OF INFECTIOUS DISEASES 182(2):640-640 Kaplan G Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection - Reply | 0 | 0 |
1349 | 8 | 15 | 1012 2000 JOURNAL OF INFECTIOUS DISEASES 182(3):983-987 Lokensgard JR; Hu SX; van Fenema EM; Sheng WS; Peterson PK Effect of thalidomide on chemokine production by human microglia | 8 | 11 |
1350 | 4 | 10 | 1228 2001 JOURNAL OF INFECTIOUS DISEASES 183(2):343-346 Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C; Natl Inst Allergy Infect Dis AIDS Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers | 1 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1351 | 10 | 15 | 1229 2001 JOURNAL OF INFECTIOUS DISEASES 184(9):1192-1196 Hanekom WA; Hughes J; Haslett PAJ; Apolles P; Ganiso V; Allin R; Goddard E; Hussey GD; Kaplan G The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children | 3 | 3 |
1352 | 13 | 15 | 1496 2002 JOURNAL OF INFECTIOUS DISEASES 185(9):1359-1363 Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H; Natl Inst Allergy Infect Dis AIDS Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267 | 5 | 5 |
1353 | 19 | 40 | 1750 2003 JOURNAL OF INFECTIOUS DISEASES 187(6):946-955 Haslett PAJ; Hanekom WA; Muller G; Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8(+) T cells in vitro | 0 | 0 |
1354 | 64 | 215 | 541 1996 JOURNAL OF INFLAMMATION 46(4):177-211 Zwingenberger K; Wnendt S Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations | 33 | 38 |
1355 | 9 | 42 | 1751 2003 JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 23(1):3-10 Bauer JA; Morrison BH; Grane RW; Jacobs BS; Borden EC; Lindner DJ IFN-alpha 2b and thalidomide synergistically inhibit tumor-induced angiogenesis | 0 | 2 |
1356 | 4 | 14 | 281 1990 JOURNAL OF INTERNAL MEDICINE 228(4):405-407 LARSSON H TREATMENT OF SEVERE COLITIS IN BEHCETS-SYNDROME WITH THALIDOMIDE (CG-217) | 19 | 35 |
1357 | 0 | 0 | 366 1993 JOURNAL OF INVESTIGATIVE DERMATOLOGY 100(4):492-492 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 0 | 0 |
1358 | 0 | 0 | 467 1995 JOURNAL OF INVESTIGATIVE DERMATOLOGY 105(3):479-479 CHARUE D; CHAUVIN E; DUGUET C; REVUZ J; BAGOT M THALIDOMIDE DECREASES THE PRODUCTION OF GM-CSF AND TNF-ALPHA IN MIXED EPIDERMAL-CELL LYMPHOCYTE-REACTION | 2 | 2 |
1359 | 0 | 0 | 542 1996 JOURNAL OF INVESTIGATIVE DERMATOLOGY 106(4):845-845 Smith C; Friednash M; Nguyen C; Knauf T; Walsh P Failure of thalidomide as an anti-angiogenesis factor in a murine melanoma model | 2 | 3 |
1360 | 0 | 0 | 622 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):179-179 Nasca MR; OToole EA; Palicharla P; West DP; Woodley DT Thalidomide increases both human keratinocyte proliferation and migration | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1361 | 0 | 0 | 623 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):721-721 Hughes MH; Brander TR; Aronson IK; Eilers D; Fiedler BC Thalidomide therapy for discoid and systemic lupus erythematosus. | 0 | 0 |
1362 | 0 | 0 | 624 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):797-797 Wong J; Brocato D; Kumar R The effect of thalidomide on murine hemangioendothelioma | 0 | 0 |
1363 | 0 | 0 | 711 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):516-516 Wolkenstein P; Latarget J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Milpied B; Bocquet H; Revuz J Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: Overmortality in treated group. | 0 | 0 |
1364 | 0 | 0 | 712 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):693-693 Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse epidermal cell apoptosis by a TNF-alpha dependent pathway. | 0 | 0 |
1365 | 25 | 52 | 830 1999 JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 15 |
1366 | 0 | 0 | 1497 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(1):212-212 Heere-Ress E; Boehm J; Hoeller C; Thallinger C; Wolff K; Pehamberger H; Jansen B Anti-tumor effect of thalidomide and dacarbazine in melanoma SCID mouse model | 0 | 0 |
1367 | 6 | 8 | 1498 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):987-988 Gaspari A Thalidomide neurotoxicity in dermatological patients: The next "STEP'' | 1 | 2 |
1368 | 17 | 24 | 1499 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):1020-1026 Bastuji-Garin S; Ochonisky S; Bouche P; Gherardi RK; Duguet C; Djerradine Z; Poli F; Revuz J; Thalidomide Neuropathy Study Grp Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients | 9 | 12 |
1369 | 19 | 46 | 1752 2003 JOURNAL OF INVESTIGATIVE DERMATOLOGY 121(5):1060-1065 Deng L; Ding WH; Granstein RD Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells | 1 | 1 |
1370 | 0 | 0 | 1927 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 122(3):A7-A7 Jin JH; Zhang W; Werth VP Thalidomide inhibits the induction of tumor necrosis factor-alpha by ultraviolet B irradiation of human keratinocytes | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1371 | 0 | 0 | 1928 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 123(2) Heere-Ress E; Boehm J; Hoeller C; Wacheck V; Thallinger C; Wolff K; Jansen B; Pehamberger H Thalidomide combined with dacarbazine enhances the anti-tumor activity in a human melanoma xenotransplantation model | 0 | 0 |
1372 | 0 | 0 | 1929 2004 JOURNAL OF INVESTIGATIVE MEDICINE 52(2):S403-S403 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide decreases fibronectin-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines. | 0 | 0 |
1373 | 23 | 30 | 1500 2002 JOURNAL OF LEUKOCYTE BIOLOGY 72(5):939-945 Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler A Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide | 2 | 6 |
1374 | 0 | 6 | 310 1991 JOURNAL OF LIQUID CHROMATOGRAPHY 14(4):667-673 ABOULENEIN HY; ISLAM MR DIRECT HPLC SEPARATION OF THALIDOMIDE ENANTIOMERS USING CELLULOSE TRIS-4-METHYLPHENYL BENZOATE CHIRAL STATIONARY PHASE | 9 | 17 |
1375 | 6 | 14 | 468 1995 JOURNAL OF LIQUID CHROMATOGRAPHY 18(2):297-309 DELON A; FAVRELIERE S; COUET W; COURTOIS PH; BOUQUET S RAPID AND SENSITIVE DETERMINATION OF THALIDOMIDE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 5 | 5 |
1376 | 10 | 15 | 713 1998 JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 21(14):2151-2163 Haque A; Stewart JT Determination of racemic thalidomide in human plasma by use of an avidin column and solid phase extraction | 3 | 5 |
1377 | 3 | 18 | 326 1992 JOURNAL OF MEDICAL GENETICS 29(10):716-723 SMITHELLS RW; NEWMAN CGH RECOGNITION OF THALIDOMIDE DEFECTS | 9 | 25 |
1378 | 1 | 27 | 1753 2003 JOURNAL OF MEDICAL GENETICS 40(7):473-478 Kohlhase J; Schubert L; Liebers M; Rauch A; Becker K; Mohammed SN; Newbury-Ecob R; Reardon W Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy | 1 | 6 |
1379 | 12 | 41 | 1013 2000 JOURNAL OF MEDICAL PRIMATOLOGY 29(1):1-10 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M; Titti F Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys | 1 | 1 |
1380 | 14 | 26 | 543 1996 JOURNAL OF MEDICINAL CHEMISTRY 39(17):3238-3240 Muller GW; Corral LG; Shire MG; Wang H; Moreira A; Kaplan G; Stirling DI Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity | 34 | 49 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1381 | 11 | 25 | 1754 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(18):3793-3799 Luzzio FA; Mayorov AV; Ng SSW; Kruger EA; Figg WD Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF alpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine | 1 | 1 |
1382 | 15 | 45 | 1755 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(24):5222-5229 Zhu XX; Giordano T; Yu QS; Holloway HW; Perry TA; Lahiri DK; Brossi A; Greig NH Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity | 2 | 2 |
1383 | 14 | 23 | 1930 2004 JOURNAL OF MEDICINAL CHEMISTRY 47(9):2219-2227 Lepper ER; Ng SSW; Gutschow M; Weiss M; Hauschildt S; Hecker TK; Luzzio FA; Eger K; Figg WD Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors | 0 | 0 |
1384 | 9 | 28 | 831 1999 JOURNAL OF NEURO-ONCOLOGY 43(2):109-114 Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro | 22 | 37 |
1385 | 9 | 23 | 1230 2001 JOURNAL OF NEURO-ONCOLOGY 51(1):41-45 Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M Thalidomide as an anti-angiogenic agent in relapsed gliomas | 12 | 22 |
1386 | 7 | 29 | 1231 2001 JOURNAL OF NEURO-ONCOLOGY 54(1):31-38 Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme | 15 | 22 |
1387 | 4 | 29 | 1232 2001 JOURNAL OF NEURO-ONCOLOGY 55(1):11-17 Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S Gliomatosis cerebri: Post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide | 0 | 4 |
1388 | 10 | 26 | 1756 2003 JOURNAL OF NEURO-ONCOLOGY 64(3):193-201 Gelati M; Corsini E; Frigerio S; Pollo B; Broggi G; Croci D; Silvani A; Boiardi A; Salmaggi A Effects of thalidomide on parameters involved in angiogenesis: an in vitro study | 0 | 1 |
1389 | 5 | 26 | 1931 2004 JOURNAL OF NEURO-ONCOLOGY 66(3):295-299 Piribauer M; Czech T; Dieckmann K; Birner P; Hainfellner JA; Prayer D; Fazeny-Dorner B; Weinlander G; Marosi C Stabilization of a progressive hemangioblastoma under treatment with thalidomide | 0 | 0 |
1390 | 8 | 30 | 1932 2004 JOURNAL OF NEURO-ONCOLOGY 67(1-2):191-200 Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1391 | 6 | 28 | 187 1986 JOURNAL OF NEUROLOGY 233(2):83-89 HESS CW; HUNZIKER T; KUPFER A; LUDIN HP THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - A PROSPECTIVE CLINICAL, NEUROPHYSIOLOGICAL AND PHARMACOGENETIC EVALUATION | 26 | 30 |
1392 | 2 | 40 | 282 1990 JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 49(6):564-581 DEIONGH RU A QUANTITATIVE ULTRASTRUCTURAL-STUDY OF MOTOR AND SENSORY LUMBOSACRAL NERVE ROOTS IN THE THALIDOMIDE-TREATED RABBIT FETUS | 3 | 3 |
1393 | 0 | 0 | 1501 2002 JOURNAL OF NUCLEAR MEDICINE 43(5):267P-267P Kinuya S; Yokoyama K; Li XF; Bai J; Michigishi T; Tonami N Radioimmunotherapy with I-131-monoclonal antibody and antiangiogenic therapy with thalidomide in colon cancer xenografts. | 0 | 0 |
1394 | 6 | 28 | 1502 2002 JOURNAL OF NUCLEAR MEDICINE 43(8):1084-1089 Kinuya S; Kawashima A; Yokoyama K; Koshida K; Konishi S; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts | 1 | 7 |
1395 | 6 | 32 | 832 1999 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 15(5):429-438 Siefert B; Pleyer U; Muller M; Hartmann C; Keipert S Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide | 0 | 10 |
1396 | 0 | 10 | 625 1997 JOURNAL OF PARENTERAL AND ENTERAL NUTRITION 21(4):233-234 Vromen A; Spira RM; Bercovier H; Berry E; Freund HR Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat | 0 | 2 |
1397 | 1 | 3 | 626 1997 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 25(2):250-251 Odeka EB; Miller V Thalidomide in oral Crohn's disease refractory to conventional medical treatment | 17 | 0 |
1398 | 12 | 23 | 833 1999 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
1399 | 10 | 18 | 1233 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(2):178-181 Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results | 10 | 17 |
1400 | 24 | 28 | 1234 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(3):322-324 Strauss RS; Das FM Thalidomide-induced sensory neuropathy | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1401 | 4 | 4 | 1757 2003 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 37(4):522-522 Ahmed M; El-Hadi S; Jenkins HR Thalidomide in Crohn disease and the risk of peripheral neuropathy | 0 | 0 |
1402 | 2 | 32 | 1503 2002 JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 24(6):488-491 Soni S; Lee DS; DiVito J; Bui AH; DeRaffele G; Radel E; Kaufman HL Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide | 0 | 1 |
1403 | 7 | 20 | 1504 2002 JOURNAL OF PEDIATRICS 140(1):125-127 Lehman TJA; Striegel KH; Onel KB Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis | 4 | 8 |
1404 | 2 | 5 | 1758 2003 JOURNAL OF PEDIATRICS 143(5):692-694 Yasui K; Misawa Y; Shimizu T; Komiyama A; Kawakami T; Mizoguchi M Thalidomide therapy for juvenile-onset entero-Behcet disease | 0 | 1 |
1405 | 7 | 34 | 1933 2004 JOURNAL OF PERIODONTOLOGY 75(1):162-168 Lima V; Vidal FDP; Rocha FAC; Brito GAC; Ribeiro RA Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats | 0 | 0 |
1406 | 4 | 40 | 1505 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 27(3-4):497-505 Trapp O; Schoetz G; Schurig V Stereointegrity of thalidomide: gas-chromatographic determination of the enantiomerization barrier | 0 | 2 |
1407 | 10 | 22 | 1506 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 29(4):761-766 Liu T; Li MX; Li QY Electrochemical behavior of thalidomide | 0 | 0 |
1408 | 2 | 29 | 1759 2003 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 31(1):19-27 Li JY; Jaworsky MS; Stirling DI The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection | 0 | 1 |
1409 | 2 | 13 | 327 1992 JOURNAL OF PHARMACEUTICAL SCIENCES 81(7):685-689 KRENN M; GAMCSIK MP; VOGELSANG GB; COLVIN OM; LEONG KW IMPROVEMENTS IN SOLUBILITY AND STABILITY OF THALIDOMIDE UPON COMPLEXATION WITH HYDROXYPROPYL-BETA-CYCLODEXTRIN | 9 | 16 |
1410 | 16 | 28 | 834 1999 JOURNAL OF PHARMACEUTICAL SCIENCES 88(1):121-125 Figg WD; Raje S; Bauer KS; Tompkins A; Venzon D; Bergan R; Chen A; Hamilton M; Pluda J; Reed E Pharmacokinetics of thalidomide in an elderly prostate cancer population | 34 | 48 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1411 | 12 | 33 | 714 1998 JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 26(4):363-383 Hoglund P; Eriksson T; Bjorkman S A double-blind study of the sedative effects of the thalidomide enantiomers in humans | 11 | 15 |
1412 | 5 | 76 | 544 1996 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 277(3):1649-1658 Arlen RR; Wells PG Inhibition of thalidomide teratogenicity by acetylsalicylic acid: Evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate | 9 | 15 |
1413 | 8 | 27 | 1235 2001 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 298(3):1221-1226 Drenth JPH; Vonk AG; Simon A; Powell R; Van der Meer JWM Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: A randomized, double-blind, placebo-controlled trial | 1 | 7 |
1414 | 10 | 40 | 1507 2002 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 300(3):768-776 Hansen JM; Harris KK; Philbert MA; Harris C Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb | 2 | 5 |
1415 | 9 | 39 | 1760 2003 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 305(3):1222-1232 Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PPM; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs | 3 | 4 |
1416 | 14 | 27 | 1934 2004 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 310(2):571-577 Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans | 0 | 0 |
1417 | 16 | 27 | 715 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 24 | 25 |
1418 | 27 | 36 | 1014 2000 JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
1419 | 13 | 23 | 1761 2003 JOURNAL OF PHARMACY AND PHARMACOLOGY 55(12):1701-1706 Eriksson T; Hoglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | 3 | 3 |
1420 | 0 | 0 | 20 1981 JOURNAL OF POST KEYNESIAN ECONOMICS 3(3):459-462 WEINTRAUB S THE CARTER ECONOMIC COUNCILS THALIDOMIDE TIP | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1421 | 0 | 0 | 1508 2002 JOURNAL OF PSYCHOPHYSIOLOGY 16(4):249-250 Stoeckel MC; Pollock B; Stoerig P; Witte OW; Schnitzler A; Seitz RJ Mislocalizations across toes as evidence for sensorimotor plasticity in thalidomide embryopathy | 0 | 0 |
1422 | 7 | 27 | 261 1989 JOURNAL OF RHEUMATOLOGY 16(2):158-163 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O TREATMENT OF REFRACTORY RHEUMATOID-ARTHRITIS - THE THALIDOMIDE EXPERIENCE | 55 | 72 |
1423 | 10 | 33 | 716 1998 JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 16 | 32 |
1424 | 10 | 15 | 835 1999 JOURNAL OF RHEUMATOLOGY 26(11):2344-2347 Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC Thalidomide in the treatment of refractory rheumatoid arthritis | 14 | 18 |
1425 | 17 | 27 | 1015 2000 JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
1426 | 19 | 32 | 1762 2003 JOURNAL OF RHEUMATOLOGY 30(12):2627-2631 Wei JCC; Chan TW; Lin HS; Huang F; Chou CT Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial | 0 | 1 |
1427 | 9 | 20 | 545 1996 JOURNAL OF SURGICAL RESEARCH 63(1):143-146 Schmidt H; Rush B; Simonian G; Murphy T; Hsieh J; Condon M Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats | 9 | 18 |
1428 | 6 | 23 | 836 1999 JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN 57(2):92-104 Shimazawa R; Takayama H; Hashimoto Y Development of novel biological response modifiers derived from thalidomide | 0 | 7 |
1429 | 2 | 54 | 48 1982 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 7(3):317-323 BARNHILL RL; MCDOUGALL AC THALIDOMIDE - USE AND POSSIBLE MODE OF ACTION IN REACTIONAL LEPROMATOUS LEPROSY AND IN VARIOUS OTHER CONDITIONS | 84 | 111 |
1430 | 8 | 39 | 119 1984 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 11(5):814-819 BARNHILL RL; DOLL NJ; MILLIKAN LE; HASTINGS RC STUDIES ON THE ANTI-INFLAMMATORY PROPERTIES OF THALIDOMIDE - EFFECTS ON POLYMORPHONUCLEAR LEUKOCYTES AND MONOCYTES | 44 | 50 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1431 | 3 | 18 | 156 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 12(1):85-90 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 25 | 42 |
1432 | 2 | 9 | 157 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(2):304-305 MIYACHI Y; NIWA Y THALIDOMIDE AND OXYGEN INTERMEDIATES | 0 | 0 |
1433 | 1 | 3 | 158 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(2):305-305 BARNHILL RL THALIDOMIDE AND OXYGEN INTERMEDIATES - REPLY | 0 | 0 |
1434 | 1 | 3 | 159 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT - REPLY | 1 | 1 |
1435 | 1 | 2 | 160 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 BRODTHAGEN H SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 1 | 1 |
1436 | 3 | 10 | 188 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):282-283 ARONSON IK; WEBER L; WEST D; BUYS C; REDER A; ANTEL J THALIDOMIDE AND LYMPHOCYTE FUNCTION | 6 | 6 |
1437 | 2 | 3 | 189 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):283-283 MILLIKAN LE; HASTINGS RC THALIDOMIDE AND LYMPHOCYTE FUNCTION - REPLY | 0 | 1 |
1438 | 13 | 39 | 262 1989 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 20(6):1060-1063 GRINSPAN D; BLANCO GF; AGUERO S TREATMENT OF APHTHAE WITH THALIDOMIDE | 9 | 24 |
1439 | 2 | 13 | 283 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(3):523-525 RADEFF B; KUFFER R; SAMSON J RECURRENT APHTHOUS ULCER IN PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 18 | 30 |
1440 | 3 | 13 | 284 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(5):941-944 RUSTIN MHA; GILKES JJH; ROBINSON TWE PYODERMA-GANGRENOSUM ASSOCIATED WITH BEHCETS-DISEASE - TREATMENT WITH THALIDOMIDE | 14 | 27 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1441 | 3 | 6 | 367 1993 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 28(2):271-272 GHIGLIOTTI G; REPETTO T; FARRIS A; ROY MT; DEMARCHI R THALIDOMIDE - TREATMENT OF CHOICE FOR APHTHOUS ULCERS IN PATIENTS SEROPOSITIVE FOR HUMAN-IMMUNODEFICIENCY-VIRUS | 31 | 39 |
1442 | 14 | 44 | 469 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 32(5):866-869 CARLESIMO M; GIUSTINI S; ROSSI A; BONACCORSI P; CALVIERI S TREATMENT OF CUTANEOUS AND PULMONARY SARCOIDOSIS WITH THALIDOMIDE | 48 | 84 |
1443 | 4 | 18 | 470 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(2):380-382 MANDERS SM; KOSTMAN JR; MENDEZ L; RUSSIN VL THALIDOMIDE-RESISTANT HIV-ASSOCIATED APHTHAE SUCCESSFULLY TREATED WITH GRANULOCYTE-COLONY-STIMULATING FACTOR | 1 | 7 |
1444 | 3 | 6 | 471 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(5):837-838 BERGER TG; HOFFMAN C; THIEBERG MD PRURIGO NODULARIS AND PHOTOSENSITIVITY IN AIDS - TREATMENT WITH THALIDOMIDE | 14 | 23 |
1445 | 74 | 101 | 546 1996 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 35(6):969-979 Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses | 78 | 117 |
1446 | 9 | 14 | 717 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 38(3):490-491 Hecker MS; Lebwohl MG Recalcitrant pyoderma gangrenosum: Treatment with thalidomide | 14 | 21 |
1447 | 7 | 10 | 718 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(2):293-295 Warren KJ; Nopper AJ; Crosby DL Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus | 7 | 9 |
1448 | 10 | 18 | 719 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(5):835-838 Lee JB; Koblenzer PS Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report | 14 | 29 |
1449 | 6 | 6 | 1236 2001 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 45(6):965-966 George SJ; Hsu S Lichen planopilaris treated with thalidomide | 3 | 6 |
1450 | 7 | 15 | 1509 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(2):S193-S195 Duong DHJ; Moxley RT; Kellman RM; Pincus SH; Gaspari AA Thalidomide therapy for cicatricial pemphigoid | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1451 | 7 | 10 | 1510 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(6):967-968 Boyd AS; King LE; Boyd AS Thalidomide-induced remission of lichen planopilaris | 0 | 0 |
1452 | 10 | 14 | 1763 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(4):548-552 Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV Dermatologic side effects of thalidomide in patients with multiple myeloma | 3 | 4 |
1453 | 9 | 12 | 1764 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(5):S89-S91 Alfadley A; Al Rayes H; Hussein W; Al Dalaan A; Al-Aboud K Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus | 0 | 0 |
1454 | 25 | 45 | 1935 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(2):235-241 Nguyen YT; Dupuy A; Cordoliani F; Vignon-Pennamen MD; Lebbe C; Morel P; Rybojad M Treatment of cutaneous sarcoidosis with thalidomide | 0 | 0 |
1455 | 0 | 0 | 1936 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(3):P78-P78 Wu JJ; Pang KR; Hsu S; Tyring SK Thalidomide: A review of new indications | 0 | 0 |
1456 | 13 | 23 | 1937 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(1):126-131 Sansbury JC; Cocuroccia B; Jorizzo JL; Gubinelli E; Gisondi P; Girolomoni G Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients | 0 | 0 |
1457 | 3 | 3 | 1938 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(3):480-481 Jouanique C; Reygagne P; Bachelez H; Dubertret L Thalidomide is ineffective in the treatment of lichen planopilaris | 0 | 0 |
1458 | 0 | 0 | 1016 2000 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 35(2):172A-173A Bozkurt B; Chee A; Lee-Jackson D; Deswal A; Zeldis JB; Mann DL Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF | 0 | 2 |
1459 | 11 | 52 | 1765 2003 JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
1460 | 0 | 0 | 1511 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:641A-641A Don BR; Vu JT; Eriksson T; Scheffler M; Kaysen GA Thalidomide is rapidly metabolized in hemodialysis patients and has a 3-fold increase in clearance during dialysis. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1461 | 0 | 0 | 1512 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:733A-734A Yudis M; Sirota RA; Stein HD; Snipes ER; Gronich JH; Ghantous VE; Collins DM Renal failure (RF) in multiple myeloma (MM) - Possible association with pamidronate and thalidomide. | 0 | 0 |
1462 | 0 | 0 | 1766 2003 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14:807A-807A Yaqub MS Acute renal failure in multiple myeloma patient receiving thalidomide and zoledronic acid infusion. | 0 | 0 |
1463 | 0 | 0 | 1767 2003 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |
1464 | 9 | 20 | 411 1994 JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2 (9):2063-2067 REEPMEYER JC; RHODES MO; COX DC; SILVERTON JV CHARACTERIZATION AND CRYSTAL-STRUCTURE OF 2 POLYMORPHIC FORMS OF RACEMIC THALIDOMIDE | 3 | 4 |
1465 | 3 | 16 | 1513 2002 JOURNAL OF THE CHINESE CHEMICAL SOCIETY 49(3):383-385 Chang MY; Chang CH; Chen ST; Chang NC A synthesis of thalidomide | 0 | 9 |
1466 | 0 | 1 | 1514 2002 JOURNAL OF THE HISTORY OF BIOLOGY 35(2):387-389 Keiner C Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
1467 | 0 | 0 | 627 1997 JOURNAL OF THE NATIONAL CANCER INSTITUTE 89(20):1480-1481 Saphir A Jekyll and Hyde: A new license for thalidomide? | 5 | 7 |
1468 | 0 | 0 | 1515 2002 JOURNAL OF THE NATIONAL CANCER INSTITUTE 94(17):1270-1272 Friedrich MJ Despite checkered past, thalidomide and its analogues show potential | 0 | 0 |
1469 | 2 | 6 | 1939 2004 JOURNAL OF THE ROYAL SOCIETY OF MEDICINE 97(9):443-443 de Savary N; Lee R; Vaidya B Severe hypothyroldism after thalidomide treatment | 0 | 0 |
1470 | 0 | 0 | 1940 2004 JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION 11(2):275A-275A Dharia SP; Steinkampf MP; Parker CR; Grubbs CJ; Crockett S The impact of thalidomide on ovarian function. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1471 | 1 | 144 | 120 1984 JOURNAL OF THEORETICAL BIOLOGY 110(3):461-486 SHULL GE DIFFERENTIAL INHIBITION OF PROTEIN-SYNTHESIS - A POSSIBLE BIOCHEMICAL-MECHANISM OF THALIDOMIDE TERATOGENESIS | 4 | 6 |
1472 | 6 | 10 | 1768 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 2 | 2 |
1473 | 8 | 21 | 1769 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):445-449 Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment | 2 | 2 |
1474 | 8 | 12 | 1770 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(12):2691-2692 Arkel YS; Ku DHW; Thurston AL The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)- alpha-stimulated cells | 0 | 0 |
1475 | 6 | 33 | 1941 2004 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2(2):327-334 Kaushal V; Kaushal GP; Melkaveri SN; Mehta P Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology | 0 | 0 |
1476 | 0 | 0 | 1771 2003 JOURNAL OF UROLOGY 169(4):233-233 Clark PE; Hall MC; Ridenhour KP; Stindt D; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma | 0 | 0 |
1477 | 0 | 0 | 720 1998 JOURNAL OF VASCULAR RESEARCH 35:54-54 Baatz H; Tonnessen B; Pleyer U; Hartmann C Antiinflammatory action of thalidomide: Modulation of leukocyte-endothelium interaction | 0 | 0 |
1478 | 0 | 0 | 628 1997 JOURNAL OF WOMENS HEALTH 6(6):614-615 White K Thalidomide may be approved after decades-long US ban | 0 | 0 |
1479 | 0 | 0 | 89 1983 KEMISK TIDSKRIFT 95(12):74-74 LEVERBECK K SECRET TEST REVEALS THE MUTAGENIC EFFECT OF THALIDOMIDE | 0 | 0 |
1480 | 0 | 0 | 472 1995 KIDNEY INTERNATIONAL 47(2):672-672 RIFLKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM THALIDOMIDE AS TREATMENT FOR REFRACTORY SYSTEMIC VASCULITIS - POSSIBLE MECHANISM OF ACTION | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1481 | 0 | 0 | 21 1981 LANCET 2(8242):368-368 MCBRIDE WG ANOTHER, LATE THALIDOMIDE ABNORMALITY | 1 | 1 |
1482 | 1 | 1 | 22 1981 LANCET 2(8245):510-511 [Anon] THALIDOMIDE - 20 YEARS ON | 0 | 0 |
1483 | 0 | 4 | 121 1984 LANCET 2(8394):98-99 NIELSEN H; BENNIKE T THALIDOMIDE ENHANCES DEFECTIVE MONOCYTE FUNCTION IN LEPROMATOUS LEPROSY | 6 | 8 |
1484 | 0 | 5 | 122 1984 LANCET 2(8396):205-206 [Anon] DEBENDOX IS NOT THALIDOMIDE | 0 | 0 |
1485 | 2 | 11 | 123 1984 LANCET 2(8417):1424-1426 JENKINS JS; POWELL RJ; ALLEN BR; LITTLEWOOD SM; MAURICE PDL; SMITH NJ THALIDOMIDE IN SEVERE OROGENITAL ULCERATION | 25 | 35 |
1486 | 0 | 10 | 161 1985 LANCET 1(8423):288-289 LEHNER T; SULLIVAN FM THALIDOMIDE, OROGENITAL ULCERS, AND THE RISK OF TERATOGENESIS | 1 | 3 |
1487 | 1 | 2 | 162 1985 LANCET 1(8427):511-511 JENKINS S; POWELL RJ; ALLEN BR; LITTLEWOOD S; MAURICE PD; SMITH NJ THALIDOMIDE, OROGENITAL ULCERS, AND RISK OF TERATOGENICITY | 2 | 3 |
1488 | 5 | 15 | 163 1985 LANCET 2(8446):80-81 [Anon] THALIDOMIDE IN DERMATOLOGY AND LEPROSY | 7 | 0 |
1489 | 2 | 8 | 164 1985 LANCET 2(8450):331-331 CRAWFORD CL THALIDOMIDE AND LEPROSY | 1 | 1 |
1490 | 3 | 4 | 234 1988 LANCET 1(8577):117-117 LIM SH; MCWHANNELL A; VORA AJ; BOUGHTON BJ SUCCESSFUL TREATMENT WITH THALIDOMIDE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 32 | 35 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1491 | 3 | 5 | 235 1988 LANCET 1(8581):359-359 SAURAT JH; CAMENZIND M; HELG C; CHAPUIS B THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 26 | 31 |
1492 | 2 | 6 | 236 1988 LANCET 1(8589):827-827 VOGELSANG GB; SANTOS GW; COLVIN OM; CHEN TL THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 12 | 25 |
1493 | 2 | 3 | 237 1988 LANCET 2(8610):568-568 RINGDEN O; ASCHAN J; WESTERBERG L THALIDOMIDE FOR SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE | 8 | 9 |
1494 | 2 | 2 | 238 1988 LANCET 2(8620):1135-1135 MCCARTHY DM; KANFER E; TAYLOR J; BARRETT AJ THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 19 | 21 |
1495 | 3 | 3 | 239 1988 LANCET 2(8623):1317-1317 HENEY D; LEWIS IJ; BAILEY CC THALIDOMIDE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN | 9 | 14 |
1496 | 3 | 3 | 285 1990 LANCET 335(8701):1343-1343 GORIN I; VILETTE B; GEHANNO P; ESCANDE JP THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 21 | 31 |
1497 | 1 | 4 | 286 1990 LANCET 335(8705):1591-1591 YOULE M; HAWKINS D; GAZZARD B THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 9 | 11 |
1498 | 1 | 4 | 311 1991 LANCET 337(8738):436-437 WILLIAMS I; WELLER IVD; MALIN A; ANDERSON J; WATERS MFR THALIDOMIDE HYPERSENSITIVITY IN AIDS | 26 | 34 |
1499 | 1 | 5 | 328 1992 LANCET 339(8789):365-365 WINTER W; FRANKUS E THALIDOMIDE ENANTIOMERS | 12 | 18 |
1500 | 5 | 7 | 329 1992 LANCET 339(8792):549-550 BESSIS D; GUILLOT B; MONPOINT S; DANDURAND M; GUILHOU JJ THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 27 | 31 |